News

news-zephyrus.jpg
Jul 29, 2019
A patient with idiopathic pulmonary fibrosis, enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with FibroGen’s investigational therapy pamrevlumab, the company announced.

Pages